Compare Biocon with ALEMBIC - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs ALEMBIC - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

ALEMBIC 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON ALEMBIC BIOCON /
ALEMBIC
 
P/E (TTM) x 31.6 56.6 55.8% View Chart
P/BV x 3.8 4.9 77.1% View Chart
Dividend Yield % 0.3 0.2 125.1%  

Financials

 BIOCON    ALEMBIC
EQUITY SHARE DATA
    BIOCON
Mar-19
ALEMBIC
Mar-18
BIOCON /
ALEMBIC
5-Yr Chart
Click to enlarge
High Rs70772 982.4%   
Low Rs55434 1,633.6%   
Sales per share (Unadj.) Rs91.94.7 1,955.2%  
Earnings per share (Unadj.) Rs16.76.1 273.8%  
Cash flow per share (Unadj.) Rs24.26.2 387.1%  
Dividends per share (Unadj.) Rs1.000.20 500.0%  
Dividend yield (eoy) %0.20.4 42.0%  
Book value per share (Unadj.) Rs101.640.7 250.0%  
Shares outstanding (eoy) m600.00267.03 224.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.911.3 60.9%   
Avg P/E ratio x37.78.7 435.0%  
P/CF ratio (eoy) x26.18.5 307.7%  
Price / Book Value ratio x6.21.3 476.4%  
Dividend payout %6.03.3 182.6%   
Avg Mkt Cap Rs m378,33014,139 2,675.7%   
No. of employees `0006.1NA-   
Total wages/salary Rs m11,653207 5,618.6%   
Avg. sales/employee Rs Th8,994.3NM-  
Avg. wages/employee Rs Th1,900.7NM-  
Avg. net profit/employee Rs Th1,635.3NM-  
INCOME DATA
Net Sales Rs m55,1441,255 4,393.2%  
Other income Rs m1,444370 390.1%   
Total revenues Rs m56,5881,625 3,481.5%   
Gross profit Rs m15,883111 14,296.1%  
Depreciation Rs m4,47838 11,846.6%   
Interest Rs m7092 41,705.9%   
Profit before tax Rs m12,140442 2,747.8%   
Minority Interest Rs m90-   
Prior Period Items Rs m01,212 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,12324 8,864.3%   
Profit after tax Rs m10,0261,630 615.1%  
Gross profit margin %28.88.9 325.4%  
Effective tax rate %17.55.4 322.6%   
Net profit margin %18.2129.8 14.0%  
BALANCE SHEET DATA
Current assets Rs m48,2281,867 2,583.0%   
Current liabilities Rs m30,376591 5,138.0%   
Net working cap to sales %32.4101.6 31.8%  
Current ratio x1.63.2 50.3%  
Inventory Days Days6894 72.5%  
Debtors Days Days8674 116.3%  
Net fixed assets Rs m64,1301,791 3,580.9%   
Share capital Rs m3,000534 561.7%   
"Free" reserves Rs m57,98010,324 561.6%   
Net worth Rs m60,98010,858 561.6%   
Long term debt Rs m15,76641 38,267.0%   
Total assets Rs m121,92411,591 1,051.9%  
Interest coverage x18.1260.9 6.9%   
Debt to equity ratio x0.30 6,813.6%  
Sales to assets ratio x0.50.1 417.6%   
Return on assets %8.814.1 62.5%  
Return on equity %16.415.0 109.5%  
Return on capital %16.815.2 110.3%  
Exports to sales %28.11.5 1,819.3%   
Imports to sales %18.921.0 89.9%   
Exports (fob) Rs m15,50619 79,927.8%   
Imports (cif) Rs m10,399263 3,948.9%   
Fx inflow Rs m15,50619 79,927.8%   
Fx outflow Rs m10,399264 3,941.7%   
Net fx Rs m5,107-244 -2,089.4%   
CASH FLOW
From Operations Rs m11,546236 4,896.5%  
From Investments Rs m-7,138-224 3,186.6%  
From Financial Activity Rs m-2,417-27 9,086.5%  
Net Cashflow Rs m2,103-15 -14,209.5%  

Share Holding

Indian Promoters % 40.4 64.0 63.1%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 0.2 4,200.0%  
FIIs % 10.7 9.7 110.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 26.1 76.2%  
Shareholders   109,995 54,701 201.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   DIVIS LABORATORIES  WOCKHARDT  SUN PHARMA  PANACEA BIOTECH  FDC  

Compare BIOCON With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tanks 531 Points; Reliance Industries & IndusInd Bank Fall 5%(Closing)

Indian share markets witnessed huge selling pressure today and failed to hold on to their opening gains as profit booking and weakness across all sectors erased gains.

Related Views on News

BIOCON Announces Quarterly Results (3QFY21); Net Profit Down 19.7% (Quarterly Result Update)

Jan 25, 2021 | Updated on Jan 25, 2021

For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY21); Net Profit Up 3.5% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, ALEMBIC LTD has posted a net profit of Rs 21 m (up 3.5% YoY). Sales on the other hand came in at Rs 131 m (down 49.7% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

One Chart to See Before You Sell(Fast Profits Daily)

Jan 22, 2021

In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.

Invest in the Multibaggers of 2021 and Beyond(Profit Hunter)

Jan 21, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Jan 25, 2021 (Close)

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS